Antiestrogens include agents such as tamoxifen, toremifene, raloxifene, and fulvestrant. Currently, tamoxifen is the only drug approved for use in breast cancer chemoprevention, and it remains the treatment of choice for most women with hormone receptor positive, invasive breast carcinoma. While antiestrogens have been available since the early 1970s, we still do not fully understand their mechanisms of action and resistance. Essentially, two forms of antiestrogen resistance occur: de novo resistance and acquired resistance. Absence of estrogen receptor (ER) expression is the most common de novo resistance mechanism, whereas a complete loss of ER expression is not common in acquired resistance. Antiestrogen unresponsiveness appears to be the major acquired resistance phenotype, with a switch to an antiestrogen-stimulated growth being a minor phenotype. Since antiestrogens compete with estrogens for binding to ER, clinical response to antiestrogens may be affected by exogenous estrogenic exposures. Such exposures include estrogenic hormone replacement therapies and dietary and environmental exposures that directly or indirectly increase a tumor's estrogenic environment. Whether antiestrogen resistance can be conferred by a switch from predominantly ERa to ERb expression remains unanswered, but predicting response to antiestrogen therapy requires only measurement of ERa expression. The role of altered receptor coactivator or corepressor expression in antiestrogen resistance also is unclear, and understanding their roles may be confounded by their ubiquitous expression and functional redundancy. We have proposed a gene network approach to exploring the mechanistic aspects of antiestrogen resistance. Using transcriptome and proteome analyses, we have begun to identify candidate genes that comprise one component of a larger, putative gene network. These candidate genes include NFjB, interferon regulatory factor-1, nucleophosmin, and the X-box binding protein-1. The network also may involve signaling through ras and MAPK, implicating crosstalk with growth factors and cytokines. Ultimately,
Introduction
Antiestrogens primarily act by competing with estrogens for binding to the estrogen receptor (ER) and are the most widely administered endocrine agents for the management of ER-expressing breast cancers. The first antiestrogens were generated in the mid-1950s as fertility agents and included ethamoxytriphetol (MER-25) and clomiphene. The ability of these compounds to induce responses in some breast cancer patients soon became apparent (Kistner and Smith, 1960) , but the compounds induced significant toxicity (Herbst et al., 1964) . In the early 1970s, the first study in breast cancer patients was published with a new antiestrogen tamoxifen (TAM, ICI 46474) (Cole et al., 1971) . Over the next 17 years, the total exposure to TAM reached 1.5 million patient years (Litherland and Jackson, 1988) and other selective estrogen receptor modulators (SERMs) are being developed and studied. TAM is now the most frequently prescribed antiestrogen, and compelling data have demonstrated a significant overall survival benefit with the administration of this agent in breast cancer patients with endocrine responsive disease (EBCTCG, 1992 (EBCTCG, , 1998 .
When compared with cytotoxic chemotherapy, antiestrogens are well tolerated and are associated with mostly minor toxicities (Love, 1989) . Common side effects associated with TAM therapy include vasomotor symptoms, gastrointestinal disturbance, atrophic vaginitis, and changes in sexual functioning (Day et al., 1999) . While the frequency and severity of hot flashes and other toxicities can be particularly unpleasant for some women, remarkably few discontinue TAM because of these side effects. Medical indications for the prompt discontinuation of therapy include associated venous thromboembolic disease and endometrial cancer (typically invasive adenocarcinoma, although uterine sarcomas have been reported). The incidence of these events is very low, and screening methods for both deep vein thrombosis and endometrial abnormalities exist. However, these increased risks must be considered in the light of the potential benefits-particularly in the case of healthy women considering TAM in the setting of chemoprevention as opposed to active treatment. The development of both venous thromboembolic disease and endometrial cancer is attributed to the estrogenic effects of TAM and may be abrogated by the development of more SERMs (e.g., raloxifene) or of pure ER antagonists (e.g., ICI 182,780; fulvestrant) (Robertson, 2001) .
Some antiestrogens produce beneficial effects beyond their ability to inhibit existing breast cancers. The most convincing evidence supports an association between TAM treatment and a marked reduction in the risk of developing a contralateral breast cancer (EBCTCG, 1992) and a significant reduction in the incidence and severity of osteoporosis in postmenopausal women (Freedman et al., 2001; Kinsinger et al., 2002) . Several early studies suggested a reduction in the risk of cardiovascular disease with TAM therapy, but this is not consistently reported (EBCTCG, 1998; Fisher et al., 1998) . When observed, the cardiovascular benefit was usually attributed to the estrogenic effects of TAM; both estrogens and TAM produce apparently beneficial changes in serum triglyceride and cholesterol concentrations (Joensuu et al., 2000) , perhaps through effects mediated by apolipoprotein E (Liberopoulos et al., 2002) . However, these findings must be considered in the light of recent large studies of estrogenic hormone replacement therapy (HRT) that either failed to identify an HRT-induced reduction in coronary heart disease (Hulley et al., 1998; Grady et al., 2002; WHI, 2002) and stroke (Viscoli et al., 2001; WHI, 2002) , or demonstrated an increase in the risk of these diseases.
An overview of antiestrogen resistance
Despite the relative safety and significant antineoplastic and chemopreventive activities of antiestrogens, most initially responsive breast tumors acquire resistance (Clarke et al., 2001b) . It is unlikely that any single mechanism or single gene confers antiestrogen resistance. Rather, several mechanisms likely exist that encompass pharmacologic, immunological, and molecular events. These mechanisms, none of which are fully understood, likely vary within tumors. Intratumor variability in antiestrogen responsiveness will reflect the presence of multiple cell subpopulations (Clarke et al., 1990a) . Since breast cancers appear highly plastic and adaptable to selective pressures, the intratumor diversity in antiestrogen responsive subpopulations also likely changes over time. Tumors appear capable of dynamically remodeling their cell populations in response to changes in host immunity or endocrinology, or the administration of local or systemic therapies. This plasticity is probably both cellular (some existing populations die out/back while other populations become dominant) and molecular (new cell populations emerge as individual cells/populations adapt their phenotypes by modifying their transcriptomes/proteomes).
Since the major pharmacologic and immunologic mechanisms of antiestrogen resistance have been previously reviewed (Clarke et al., 2001b) , we will focus on the role of molecular signaling through ER-mediated activities in antiestrogen responsiveness. Antiestrogen resistance can be either de novo or acquired. The most common and best defined mechanism of de novo resistance is the absence of both ER and progesterone receptor (PR) expressions. However, we fail to predict response to antiestrogens in approximately 25% of ER þ /PR þ , 66% of ER þ /PRÀ, and 55% of ERÀ/ PR þ breast tumors (Honig, 1996) . Many ER þ and/or PR þ breast tumors are already resistant by the time of diagnosis and the resistance mechanism in these tumors is unknown.
Overall, a loss of antiestrogen responsiveness by initially responsive tumors is likely to be the most common acquired resistance phenotype. Most initially antiestrogen responsive tumors retain levels of ER expression at recurrence on antiestrogen therapy that would still define them as being ER þ (Encarnacion et al., 1993; Kuukasjarvi et al., 1996; BachleitnerHofmann et al., 2002) . Most data are for TAM treatment; ICI 182780, which causes degradation of ER (Dauvois et al., 1992) , may have a greater potential for producing ERÀ tumors (Kuukasjarvi et al., 1996) . From our in vitro studies, loss of ER is not required to achieve resistance to either ICI 182,780 or TAM (Bru¨nner et al., 1993b (Bru¨nner et al., , 1997 . The loss of ER expression upon recurrence despite adjuvant TAM therapy has been reported in less than 25% of tumors (Kuukasjarvi et al., 1996; Bachleitner-Hofmann et al., 2002) . Overall, a loss of ER expression does not seem to be the major mechanism driving acquired antiestrogen resistance.
A different resistance phenotype has been described in human breast cancer xenografts that exhibit a switch to a TAM-stimulated phenotype. This mechanism of clinical but not pharmacologic resistance may not be the dominant antiestrogen resistance phenotype. If the prevalence of acquired resistance phenotypes in ER þ tumors broadly reflects what is seen in de novo resistance, then the dominant resistance phenotype is a loss of antiestrogen responsiveness.
Whether the continued expression of ER is required for antiestrogen-resistant tumor growth or survival is not known. However, responses to aromatase inhibitors after an initial response and then failure on TAM are common (Buzdar and Howell, 2001 ) and strongly suggest that some TAM-resistant tumors retain a degree of estrogen responsiveness. Where durations of responses to second-line endocrine manipulations are short, truly estrogen-independent cell populations are either already present at the time of recurrence and/or many cells in the tumor are able to adapt rapidly to further changes in their endocrine environment. Very short response durations or disease stabilization may reflect the withdrawal of a mitogenic stimulus that is not required for the survival or basal proliferation of most cells in the tumor.
Antiestrogens
TAM is a triphenylethylene and its triaryl structure has been widely copied in the design of new compounds. Several TAM derivatives are already available, including toremifene (chloro-tamoxifen) and droloxifene (3-hydroxytamoxifen). Not surprisingly, both drugs are essentially equivalent to TAM in terms of their antitumor activities and toxicities (Roos et al., 1983; Pyrhonen et al., 1999) , so neither is widely used in clinical practice.
The characteristic of raloxifene that has attracted the most interest is its apparent lack of estrogenic effects in the uterus, resulting in great interest in this drug's potential role in breast cancer chemoprevention. Subgroup analysis of the data from the Multiple Outcomes of Raloxifene (MORE) trial revealed that administration of raloxifene was associated with a 75% reduction in the incidence of invasive breast cancer without a concurrent increase in the incidence of endometrial cancers (Cummings et al., 1999) . This finding has led to the ongoing randomized study of TAM and raloxifene (STAR) in breast cancer prevention. Raloxifene still acts as an antiestrogen in the brain, increasing the incidence of hot flashes (Davies et al., 1999) . A high incidence of severe hot flashes is problematic for a drug to be administered for approximately 5 years to otherwise apparently healthy women. Raloxifene was recently approved by the Food and Drug Administration for the treatment and prevention of osteoporosis in postmenopausal women. While a benzothiophene, raloxifene (keoxifene; LY 156,758) has a three-dimensional structure broadly similar to the triphenylethylenes. ICI 182, 780 (Faslodex; Fulvestrant) is among the more promising new antiestrogens. Unlike TAM, ICI 182,780 is a steroidal ER inhibitor that is often described as a 'pure' antagonist with no estrogenic activity. This is in comparison to the triphenylethylene and benzothiophene antiestrogens, which are nonsteroidal, competitive ER inhibitors with partial agonist activity. The pure antagonist is characterized by antineoplastic activity in breast cancer and is devoid of uterotropic effects. However, the lack of agonist activity limits beneficial effects in bone. Whether ICI 182,780 also will increase hot flashes depends on whether it reaches adequate concentrations in the brain. Unlike TAM , ICI 182,780 appears to be a substrate for the P-glycoprotein efflux pump (De Vincenzo et al., 1996) , a major contributor to the blood-brain barrier (Cordon-Cardo et al., 1989) . Consistent with this observation, initial studies suggest that this antiestrogen does not enter the brain in high concentrations . Pure antagonists may further exacerbate bone loss, a concern that also applies to aromatase inhibitors (Dowsett, 1997) , but this issue may be addressed with the concurrent use of bisphosphonates or other therapies for osteoporosis. Clinical experience with ICI 182,780 has been reviewed by Howell (2001) .
Antiestrogens and breast cancer treatment
Antiestrogens are effective in the adjuvant, metastatic, and chemopreventive settings and clearly induce significant increases in overall survival in some breast cancer patients (EBCTCG, 1992 (EBCTCG, , 1998 . Unlike aromatase inhibitors (inhibit estradiol biosynthesis), which are administered as single agents only to women with nonfunctioning ovaries, TAM can be given irrespective of menopausal status. In the adjuvant setting, TAM is administered at a daily oral dose of 20 mg, and several studies have now shown that the optimal duration of treatment is 5 years. While shorter (2 years) and longer (10 years) treatment durations produce notable responses, the risk : benefit ratios are strongly in favor of 5 years of treatment (Stewart et al., 1996; EBCTCG, 1998) .
While molecular predictors of tumor responsiveness are rare for most breast cancer treatments, expressions of ER and PR strongly predict for a response to antiestrogens. Up to 75% of breast tumors expressing both receptors (ER þ /PR þ ) respond to TAM. Response rates are somewhat lower in ER þ /PRÀ tumors (B34%) and ERÀ/PR þ tumors (45%). The response rate in ERÀ/PR þ may be an overestimate; relatively few tumors with this phenotype have been evaluated and the ERÀ assessment may include false-negative ER measurements. Only a small proportion of ERÀ/PRÀ tumors respond to antiestrogens (o10%), perhaps also reflecting false-negative ER measurements. Indeed, the most recent meta-analysis from the Early Breast Cancer Trialists Collaborative Group (EBCTCG) found no significant reduction in recurrence rates in patients with ER-poor tumors who received adjuvant TAM (EBCTCG, 1998) .
Results of the 1998 EBCTCG meta-analysis found limited evidence for a TAM-induced increase in the risk of death from any cause in women with ER-poor tumors. Why TAM might be detrimental to some women is unclear. However, ERÀ tumors are known to exhibit a more aggressive phenotype associated with lower rates of overall survival (Aamdal et al., 1984) and would be expected to recur earlier and more frequently. Estrogenic effects of TAM in these women also could have increased the number of deaths from cardiovascular disease and stroke, reflecting the data noted above from recent studies of estrogenic HRT use (Viscoli et al., 2001; WHI, 2002) .
Antiestrogens and breast cancer chemoprevention
TAM's ability to inhibit contralateral breast cancers and relatively low incidence of serious side effects led to studies into its potential use as a chemopreventive agent for patients with a high breast cancer risk. Three large, randomized, chemoprevention studies with TAM have been performed to date: the NSABP P-1 trial (n ¼ 13 388 participants) (Fisher et al., 1998) , the Royal Marsden Trial (n ¼ 2471 participants) (Powles et al., 1998) , and the Italian Chemoprevention Trial (n ¼ 5408 participants) (Veronesi et al., 1998) . Outcomes have been mixed: no significant reduction in risk was seen in the initial reports of either the UK or Italian trials, whereas the P-1 trial reported significant reductions in the incidence of both noninvasive (50%) and invasive (49%) breast cancers. A recent update on the Italian Trial reports an 82% TAM-induced reduction in the breast cancer risk among women at high risk for ER þ breast cancer (Veronesi et al., 2003) . In the NSABP trial, reductions in breast tumor incidence were seen only in the incidences of ER þ tumors (Fisher et al., 1998) . Reasons for the disparities among the trials have been widely discussed; these tend to focus on differences in patient populations, subject eligibility criteria, and study size. Results from the NSABP P-1 trial, which are broadly consistent with the 39% reduction in contralateral breast cancer incidence reported for TAM use (EBCTCG, 1992) , are usually considered the more definitive. These data contributed to the decision by the Federal Drug Administration (USA) in October 1998 to allow the use of TAM as a chemopreventive agent for breast cancer. More recently, NSABP has reported TAM-induced reductions in the risks of adenosis, fibrocystic disease, hyperplasia, metaplasia, fibroadenoma, and fibrosis in the P-1 trial (Tan-Chiu et al., 2003) .
Estrogens and breast cancer
Since antiestrogen action and resistance are intimately affected by estrogen exposure, we briefly address the role of estrogens in breast cancer. An association between parity and breast cancer risk was observed by the 16th century Italian physician Bernadino Ramazzini (1633-1714) in his 'De Morbis Artificium' published in 1700. The ability of ovariectomy to induce remissions in premenopausal breast cancer patients was shown by the Scottish physician George Beatson, the first clear evidence of an effective endocrine therapy for this disease (Beatson, 1896) . More recent epidemiologic data show clear associations of early age at menarche, late age at menopause (Nishizuka, 1992) , pregnancy (Hsieh et al., 1994) , obesity (Hulka and Stark, 1995) , serum estrogen concentrations (EHBCCG, 2002) , and use of estrogenic HRTs (Magnusson et al., 1999; Schairer et al., 1999 Schairer et al., , 2000 or oral contraceptives (Berger et al., 2000) with an increase in the risk of developing breast cancer. Risk appears related to the timing of exposure and whether the cancer develops during the premenopause or postmenopause (HilakiviClarke et al., 2002) .
Precisely how estrogens affect breast cancer risk remains controversial and outcome may be dependent upon the timing and duration of exposure. During the postmenopausal years, estrogenic stimuli are more closely associated with an increased breast cancer risk.
However, we have recently reviewed evidence consistent with the hypothesis that, depending on the timing of exposure, increased estrogenic exposure can be associated with a reduced risk of breast cancer (HilakiviClarke et al., 2002) . For example, estrogenic stimuli during childhood or the premenopausal years may affect breast development such that the breast is less susceptible to transformation. Estrogens may reduce breast cancer incidence in some women by altering mammary gland development and inducing the expression of genes involved in DNA repair (Hilakivi-Clarke et al., 1999a; Hilakivi-Clarke, 2000) .
For the purposes of this review, we will focus on the aspects of estrogen exposure that are associated with increased breast cancer risk and the survival/proliferation of established neoplastic breast cells. Hence, estrogens can be considered to act either as promoters (factors that stimulate the growth and/or survival of existing transformed cells) or as initiators (factors that induce the genetic damage that leads to cellular transformation). Evidence that estrogens are tumor promoters is well established from both experimental and clinical observations. For example, the growth of several human breast cancer cell lines in vitro and in vivo is stimulated by estrogenic supplementation. Indeed, such estrogenic supplementation is effective whether administered as classical estrogens (e.g., estradiol, estrone, or estriol) or plant-derived phytoestrogens such as the isoflavone genistein (Hsieh et al., 1998) . In addition, antiestrogens, aromatase inhibitors, leutinizing hormone releasing hormone agonists/antagonists, and ovariectomy are effective in the treatment of some breast cancer patients, all of which limit the interaction between a promotional (estrogenic) stimulus and cancer cells.
As tumor promoters, the effects of estrogens are related to the duration and timing of exposure. Withdrawal of an estrogenic stimulus that acts as a promoter could produce an eventual reduction in risk because it no longer promotes the growth or survival of existing cancer cells. Pregnancy produces a natural and significant increase in circulating estrogens, but only a transitory increase in breast cancer risk in young women. Indeed, if the first pregnancy was at a young age, the short-term increase may eventually translate into a lifetime reduction in breast cancer risk (Hsieh et al., 1994) . The increased breast cancer risk associated with either oral contraceptive or estrogenic HRT use is also related to the recency of use. Risk begins to reduce with the cessation of use and is highest in current users (CGHFBC, 1996; Schairer et al., 2000) .
Evidence that estrogens act as chemical initiators is more controversial. Estrogens can exhibit carcinogenic activity in some animal models; perhaps the best-known example is the ability of estrogens to induce renal cancers in Syrian hamsters (Kirkman, 1972) . However, compelling evidence that estrogens initiate mammary cancer in animals is hard to find. In the 1930s, Lacassagne (1932) performed several studies in male mice and showed that administration of large doses of estrone can induce mammary tumors. While consistent with an estrogen-mediated initiation of mammary cancer, it is possible that the mice were infected with the mouse mammary tumor virus (MMTV). Other than some transgenic/null mouse models, only in the ACI rat does estrogen administration reproducibly produce a high incidence of mammary tumors (Cavalieri and Rogan, 2002) .
Reactive estrogen semiquinone/quinone intermediates, produced by the redox cycling of estrogen metabolites hydroxylated at the C3 and C4 positions of the aromatic A-ring, are the most likely estrogen initiators (Cavalieri et al., 1997; Bishop and Tipping, 1998; Cavalieri and Rogan, 2002) . These reactive species can generate a substantial intracellular oxidative stress and directly damage DNA through the production of DNA adducts. Such events could define reactive estrogen metabolites as initiators, rather than as merely promoters of carcinogenesis. Recently, the National Toxicology Program (2003) listed, for the first time, steroidal estrogens as carcinogens.
Estrogen independence and antiestrogen resistance
Estrogen independence and antiestrogen resistance are often considered to be synonymous, which is not surprising since ERÀ tumors are definitively estrogenindependent and very rarely respond to antiestrogens, ovariectomy, or aromatase inhibitors. Nonetheless, several observations suggest that various forms of both estrogen independence and antiestrogen resistance exist and that these may be biologically and clinically very different. For example, second-line responses to aromatase inhibitors after response and recurrence on TAM are common (Goss et al., 1995; Buzdar et al., 1996) . Crossover between more similar compounds, such as other nonsteroidal antiestrogens, rarely produces secondary responses (Johnston, 2001 ), although crossover to structurally different antiestrogens can produce secondary responses in patients. Tumors that respond first to TAM (triphenylethylene) show a marked response to ICI 182,780 (steroidal) administered upon failure of the TAM therapy (Howell et al., 1995) . Similar patterns of responses were seen previously in experimental models (Bru¨nner et al., 1993b) . For example, MCF-7 human breast cancer cells were selected for the ability to grow in the absence of estrogens (Clarke et al., 1989a) . The selected cells are estrogen-independent because they no longer require estrogens for growth either in cell culture or as xenografts in athymic nude mice. However, when exposed to either 4-hydroxytamoxifen or ICI 182,780, the cells are growth inhibited both in vitro and in vivo (Clarke et al., 1989a; Bru¨nner et al., 1993a, b) .
These observations strongly imply that the ability of breast cancer cells to grow in a low or nonestrogenic environment is not always synonymous with antiestrogen resistance. Four antiestrogen resistance phenotypes have been defined (Clarke and Bru¨nner, 1995) and are shown in Table 1 . The clinical applicability of these phenotypes remains to be determined but they are useful for defining resistance phenotypes in experimental models.
Intratumor estrogens and antiestrogens and exogenous estrogenic exposures
Antiestrogens act within cells, primarily to compete with available estrogens for binding to ER. Thus, the antiestrogenic potency of any compound is related to its affinity for ER relative to that of any estrogens present and the concentrations of both the antiestrogens and estrogens. The data in Table 2 show the relative affinities of the primary estrogens, antiestrogens and their major metabolites, and selected environmental estrogens and phytoestrogens. Intratumor estrogen concentrations are affected by several factors including serum estrogen concentrations and local estrogen production within the breast. Serum estrogen concentrations are affected by the presence or absence of functional ovaries and exogenous estrogen use such as HRT, some oral contraceptives, and various dietary components.
Passive diffusion into cells across the plasma membrane appears to be TAM's and estradiols's primary method of entry into cells. However, both TAM and estrogens are extensively bound to serum proteins and probably also to cellular proteins in tumor/nontumor cells within the breast (Clarke et al., 2001b) . Release from serum proteins likely occurs within the tumor vasculature, with both estrogens and antiestrogens being subsequently sequestered within tumor/nontumor cells by intracellular proteins. The lipophilicity of both hormone and drug, and the significant amount of adipose tissue in the breast, may produce a local reservoir for both estrogens and antiestrogens. However, the concentration of free drug/hormone within cells and serum may be relatively low. Intracellular sequestration of drug/hormone in tumor and stromal cells could produce a concentration gradient favoring several points regarding the pharmacokinetics of estrogens and antiestrogens. For example, intratumor concentrations of both estradiol and TAM are much higher than their respective concentrations in the serum. For estrogens, where the primary estrogen present in tumors is 17b-estradiol, both biosynthesis within the tumor and significant uptake from blood occur. The ability of estrogens and antiestrogens to compete for binding to ER is likely to reflect intracellular availability. While their respective free concentrations are largely unknown, the data in Tables 2 and 3 imply that many breast tumors should accumulate a sufficient excess of TAM and its major antiestrogenic metabolites to compete readily with intratumor estrogens. If the estimate for estradiol concentrations (1.29 nm) and the reported concentrations for TAM and its major metabolites (B3 mm TAM þ B7 mm N-desmethyltamoxifen þ B0.2 mm 4-hydroxytamoxifen) in tumors are good approximations (Table 3) , antiestrogenic metabolites may accumulate to levels up to 10 4 -fold higher than estradiol. While TAM and N-desmethyltamoxifen have relative ER binding affinities about 10% that of estradiol (Table 2) , overall, antiestrogenicity may exceed estrogenicity in most TAM-treated breast tumors by 100-fold (assuming equivalent availability).
This interpretation is consistent with the initial antiestrogenic activity of TAM seen in most ER þ breast cancers. No compelling evidence shows that TAM becomes extensively metabolized to purely estrogenic metabolites in patients with antiestrogen-resistant cancer. Furthermore, little evidence has been produced to suggest that the balance of TAM metabolism is such (Clarke et al., 2001b) . Currently, no clinically relevant ER variants/ mutants have been described that could adequately affect intratumor pharmacology to an extent sufficient to offset this balance in favor of a TAM-stimulated or other antiestrogen-resistant phenotype in a significant proportion of breast cancers. Changes in TAM influx/efflux could alter its intracellular concentrations, and limited evidence suggests that this may occur in some tumors. However, the extent to which it occurs and the mechanisms driving such changes are unclear (Clarke et al., 2001b) .
Exogenous estrogenic exposures and their effects on antiestrogen resistance
Since estrogens compete with antiestrogens for ER binding, any compound with either estrogenic activity or the ability to increase estrogen exposure could affect response to antiestrogens. Estrogenic exposures come in many forms, including plant and environmental estrogens (Hilakivi- Clarke et al., 1999b; Clarke et al., 2001a) , dietary exposures that affect the levels of endogenous estrogens (Hilakivi-Clarke et al., 1997), and estrogenic HRT (Clarke et al., 2001b) . Dietary antioxidant exposure also may affect antiestrogen responsiveness (Clarke et al., 2001b) and some women already take the most potent natural antioxidant (vitamin E) as an alternative medicine for controlling menopausal symptoms (Stampfer et al., 1993; Barton et al., 1998; Koh et al., 1999) .
The inclusion of women on HRT in some of the chemoprevention trials has been one of the issues raised to explain the lack of TAM's activity in these trials. It is unlikely that HRT would raise serum estrogens beyond levels seen in TAM responsive premenopausal women. However, the nature of the estrogenic exposure is very different between postmenopausal women on HRT and premenopausal women. More data are required to assess directly the contribution of HRT to TAM responsiveness.
Dietary exposures and tamoxifen activity
Several dietary components, including those present in dietary fats, soy, fruits, vegetables, and alcohol, have been suggested to have either protective or harmful effects on the breast. Some of these dietary factors, such as dietary fats and soy, can alter circulating estrogen levels (Lu et al., 2000) and interact with ER (Wang et al., 1996b; Collins et al., 1997; Zava and Duwe, 1997 ). TAM's ability to affect the growth of ER þ tumor cells may be altered by dietary intakes of fats and soy. Fats, soy, and other dietary components also modify other cell signaling pathways (Agarwal, 2000; Bouker and Hilakivi-Clarke, 2000; Clarke et al., 2002) . If TAM signals through the same pathways, a dietary factor might modify TAM's ability to inhibit the growth of malignant breast cells (ER-dependent or -independent interactions). Dietary components that alter signaling of a pathway that affects tumor growth independent of TAM also could either potentiate or reverse TAM's effects. Data from both in vitro and in vivo studies strongly support the hypothesis that at least some dietary factors modify TAM's actions in the breast.
Soy, dietary fat, vegetables, and antiestrogen responsiveness
High soy protein intake has been proposed to contribute to low breast cancer incidence among Asian women (Adlercreutz, 1995) . A recent meta-analysis shows that a high intake of soy is associated with a reduced risk of developing premenopausal, but not postmenopausal, breast cancer (Trock et al., 2001) . Soybeans contain large amounts of the isoflavones daidzein and genistein Adlercreutz, 1995) . Genistein has many biological effects that could potentially reduce breast cancer risk, including inhibition of tyrosine kinase, EGFR tyrosine phosphorylation, and topoisomerase II activities. It also arrests cell cycle progression at G 2 -M, induces apoptosis, has antioxidant properties, modifies eicosanoid metabolism, and inhibits in vitro angiogenesis (see the review by Messina et al., 1994) . While each of these actions of genistein could influence antiestrogen responsiveness, they occur primarily at pharmacologic rather than physiologic exposures. Humans consuming high levels of soy-based food products have less than 1 mm of circulating genistein (Messina et al., 1994) , and 30-185 mm genistein is required to induce many of the above-mentioned effects in experimental models in vitro where bioavailability is already likely to be greater than in vivo.
At physiological concentrations, genistein exhibits estrogenic properties that could enhance breast cancer risk. Genistein activates the ER (Wang et al., 1996b; Collins et al., 1997; Zava and Duwe, 1997) and induces proliferation of human breast cancer cells in vitro (Martin et al., 1978; Wang et al., 1996b) . Genistein also stimulates proliferation of mammary epithelial cells in rodents (Santell et al., 1997; Hsieh et al., 1998) and in women (Petrakis et al., 1996; McMichael-Phillips et al., 1998) . Data from ovariectomized athymic mice, representing a model of postmenopausal breast cancer, show that genistein and soy protein isolate both promote the growth of MCF-7 xenografts (Allred et al., 2001) . Furthermore, a recent study in athymic mice showed that genistein blocked the inhibitory effect of TAM on the growth of MCF-7 xenograft (Ju et al., 2002) . These results suggest caution in consuming high levels of genistein among postmenopausal women who are taking TAM for their breast cancer or to reduce their risk of developing breast cancer. Very little is known about possible interactions between high dietary fat intake and the activity of TAM. TAM has beneficial effects on some aspects of fatty acid metabolism, for example, by reducing cholesterol levels (Reckless et al., 1997) . Diets containing n-3 PUFAs can increase the efficacy of cytotoxic drugs against ERÀ human breast cancer xenografts (MDA-MB-231) (Hardman et al., 2001) . A recent study suggests that n-3 PUFAs restore TAM's ability to inhibit cell growth (DeGraffenried et al., 2003) . Oleic acid appears to affect indirectly TAM's dissociation from cellular antiestrogen binding sites (Hwang, 1987) , an effect that could increase the intracellular concentrations of free drug. Since n-3 PUFAs have many biological activities, they may play a role in modifying TAM's actions, including an ability to inhibit protein kinases (Mirnikjoo et al., 2001) . g-linolenic acid has several properties that might make it antitumorigenic. Kenny et al. (2001) have shown that g-linolenic acid reduces the growth of MCF-7 xenografts, reduces ER levels in these cells, and potentiates TAM's ability to inhibit cell growth. However, the precise mechanism of action of g-linolenic acid remains to be determined.
Cruciferous vegetables, such as broccoli, cabbage, cauliflower, and brussel sprouts contain high levels of indole-3-carbinol (I3C) and its metabolite 3,3-diindolymethane (DIM). These compounds have been shown to exhibit chemopreventive activity in multiple target organs including the breast (Bradlow et al., 1999) . Several mechanisms of action have been proposed for I3C and DIM, including changes in phase I and II enzyme activities and in cell cycle progression. Data from Katchamart and Williams (2001) show that I3C and DIM downregulate the expression of the cytochrome P-450 components that convert TAM to its more potent metabolites. Thus, these authors propose that high intake of cruciferous vegetables might reduce TAM efficacy. Vitamin A/retinoids can interact with estrogens, and some studies suggest that retinoids can increase the activity of TAM (McCormick and Moon, 1986; Anzano et al., 1994) . Little evidence from human studies exists to support directly this interaction. However, remarkably few studies have been undertaken in this area and additional data are clearly needed.
Estrogen receptors and antiestrogen resistance
Two ER genes have been identified: the classical ERa on human chromosome 6q25.1 and ERb on chromosome 14q22-25. Each receptor acts as a nuclear transcription factor that binds responsive elements (estrogen responsive elements; EREs) within the promoters of target genes (Figure 1a ) or binds to other proteins and affects their abilities to regulate transcription (e.g., AP-1, SP-1; Figure 1b ). ERa and ERb homology is limited in the transcriptional regulatory domains, particularly in the N-terminal region. Both ER homodimers and heterodimers are formed and these may differ in their ability to affect transcription at some promoters . For example, the ER binds directly to EREs, which are broadly defined consensus sequences with some tolerance to variation in their sequence. ER also binds to, and regulates the transcriptional activation of, other transcription factors including AP-1, SP-1, and at cyclic AMP response elements (CRE) (Paech et The patterns of ER expression vary in the mammary gland. In most normal mammary epithelia, the two receptors are rarely expressed in either a high proportion of cells or at very high levels. The ERa : ERb ratio may change during carcinogenesis, such that the ERa proportion increases as the cells acquire a more progressed phenotype. Whether this change reflects an increase in ERa or a decrease in ERb expression , and whether it is a function or a consequence of malignant transformation or progression is unclear. ERa appears to be the more highly expressed of the two receptors in breast tumors Speirs et al., 1999a) , at least when both are coexpressed in the same cells (Saunders et al., 2002) . However, some of the few existing studies that measured both ERa and ERb proteins have been complicated by the use of different antibodies of occasionally uncertain quality (Speirs, 2002) .
When occupied by estradiol, ERa and ERb can produce similar effects on gene regulation in simple . Transcription can be induced or repressed, with the pattern of genes affected likely reflecting the mix of coregulators available to bind to the various ER-transcription complexes formed on respective promoters. Evidence for both ligand-dependent and -independent activation exists, and it is clear that different ligands can induce different conformations in the bound ER proteins. ER ¼ estrogen receptor; in (a) the hatched elipse represents a coregulator; in (b) the split elipse represents a protein complex such as AP-1 or SP-1 ERE-driven reporter construct studies (Kuiper et al., 1996) . However, the ligand binding profiles of the two receptors may be species specific . Furthermore, at other promoters, the two receptors have very different activities. For example, ERa and ERb have opposite effects on transcription driven by AP-1, SP-1, or CRE sites in promoter-reporter assays (Paech et al., 1997; Castro-Rivera et al., 2001; Maruyama et al., 2001a; Liu et al., 2002b) . Differential regulation of cyclin D1 by ERa and ERb has been reported (Liu et al., 2002b) , and ERb can block the transcriptional activation of AP-1 by ERa (Maruyama et al., 2001b) . Changes in ER expression/activation might be important in affecting endocrine responsiveness if genes driven primarily by AP-1, SP-1, and/or CRE elements are rate limiting in affecting signaling to apoptosis/proliferation/survival.
The relative importance of ERa and ERb in affecting antiestrogen responsiveness remains to be established. However, the extensive existing data with well characterized ERa antibodies that do not recognize ERb allow for some speculation. Ligand binding ER assays (do not differentiate between ERa and ERb) and immunohistochemical detection of ER in patients' tumors (detect ERa only) broadly agree in their determination of ER-positivity and prediction of TAM sensitivity (Alberts et al., 1996; Molino et al., 1997) . Thus, whatever the role of ERb, measuring ERa is sufficient to predict whether or not a patient is likely to benefit from treatment with antiestrogen, aromatase inhibitor, or ovariectomy. These findings also would be consistent with a requirement of ERa for antiestrogen sensitivity, which is further consistent with data from most experimental models in which ERa is usually the dominant ER isoform expressed.
Since loss of ERa (i.e., the tumor phenotype changes from ERa þ to ERaÀ) is relatively uncommon as an acquired antiestrogen resistance mechanism, it seems unlikely that many resistant tumors acquire a true ERaÀ/ERb þ phenotype. If there is a role for ERb, it may be driven by changes in its expression level relative to ERa, since heterodimers are functionally important (Pettersson et al., 1997; Tyulmenkov et al., 2000) . When introduced into ERÀ MDA-MB-231 breast cancer cells, ERb produces ligand-independent inhibition of proliferation, whereas ERa-mediated effects are liganddependent (Lazennec et al., 2001) . A ligand-independent suppression of growth by ERb might confer a multihormone-resistant phenotype (Schinkel et al., 1991) (multihormone resistance is Type 4 resistance as shown in Table 1 ), since ICI 164,384 could not block the ligand-independent effect of ER expression in MDA-MB-231 cells (Lazennec et al., 2001) .
Currently, determining the relative importance of ERb expression in antiestrogen responsiveness is limited by the lack of adequate data regarding ERb protein expression in responsive and resistant breast tumors. The possible association of ERb mRNA expression with a poor prognosis (Dotzlaw et al., 1999; Speirs et al., 1999b) may further complicate matters. Only one small study (n ¼ 9 TAM resistant; n ¼ 8 TAM responsive tumors) has explored the association of ERb expression with antiestrogen resistance. The authors reported increased ERb mRNA expression in antiestrogenresistant tumors (Speirs et al., 1999a) . Nonetheless, the outcome is potentially confounded by the very small number of cases, the fact that only ERb mRNA was measured, and the possible association of ERb expression with a more aggressive phenotype (Dotzlaw et al., 1999; Speirs et al., 1999b) .
Several mutant and splice variant forms of both ERa and ERb have been reported and previously reviewed (Hopp and Fuqua, 1998; Murphy et al., 1998) . Compelling evidence that any of these are functionally relevant in driving a significant proportion of breast cancers remains largely unconvincing. For example, most data only measure mutant mRNAs that may not be translated into biologically relevant protein concentrations in cells. Most tumors that express mutant ER concurrently express the wild-type receptor, with the mutant representing a relatively small proportion of total ER. A mutant ERa (D351Y) that perceives TAM as an agonist has been described in some TAMstimulated MCF-7 cell variants (Jiang et al., 1992) . Similarly, changes in the F-region of the receptor also can affect the activities of estradiol and 4-hydroxytamoxifen . The agonist activities of raloxifene are also increased in D351Y (Liu et al., 2002a) . Expression of this mutant in breast tumors in patients has not been reported. Thus, the clinical relevance of this ER mutant or functionally similar ER mutant proteins remains unclear. However, our understanding of the role of ER mutants and variants may change in the near future (Fuqua, 2001) . Currently, little compelling evidence exists in support of mutant or splice variant ERa and/or ERb contributions to either de novo or acquired antiestrogen resistance or hormone independence (Karnik et al., 1994; LeClercq, 2002) . However, the importance of receptor mutations and varinats in other diseases suggests that a role for these modifications of ERs may yet be shown to be important.
Coregulators of estrogen receptor function and antiestrogen resistance
Whatever the ERE and/or other transcription factor bound, the ability to affect transcription of a target gene is further modified by multiple components of the transcription complex. Perhaps the most widely studied modifiers of ER-mediated transcription are the coregulators. Coregulators can be either coactivators (inducers) or corepressors (inhibitors) of gene transcription. These molecules often act by altering histone acetylation . While most studies of coregulator action have been carried out with ERa, ERb function is also affected (Tremblay et al., 1998) , as is the activity of other members of the steroid hormone receptor superfamily.
ER coregulators in several protein families have been described in recent years, almost all of which are ubiquitously expressed (Graham et al., 2000) and defined initially by their ability to affect ER-mediated transcription in simple promoter-reporter transcription assays. Considerable redundancy is evident, with many coactivators or corepressors exhibiting similar transcription regulatory effects in comparable/identical biological assays. A full understanding of the role of coregulators may be further complicated by gene promoter-, tissue-, and species-specific effects, all of which contribute to the cellular context. Thus, the pattern of other proteins expressed in a cell (cellular context) may greatly influence how and whether a specific coregulator is the dominant effector in regulating a ligand's ability to affect ER-mediated transcription (Clarke and Bru¨nner, 1996; Clarke et al., 2001b) .
The ability of an ER-driven transcription complex to recruit coregulators can be strongly ligand-dependent. For example, 4-hydroxytamoxifen induces a conformation that blocks the coactivator recognition groove in ER (Shiau et al., 1999) . Estrogens and antiestrogens have long been known to affect the physical properties of ERs (Miller et al., 1984) . The importance of ligand to receptor conformation and activation led to early conceptual models that have received renewed attention in recent years. Perhaps the most important information has come from crystallographic studies of the ER binding domain complexed with different ligands (Brzozowski et al., 1997; Pike et al., 1999; Shiau et al., 2002) . Several laboratories have used these data to describe conceptually similar models of ER function when liganded with either agonists or antagonists (Wurtz et al., 1998; Pike et al., 1999; Liu et al., 2002a , Shiau et al., 2002 . The major limitations of such studies are the use of only the ligand binding domain (requires the assumption that no other domains of the ER affect its structure) and the use of crystal structures that may or may not fully reflect receptor structure in the more complex environment of a living cell. Nonetheless, data from such studies can provide important molecular insights into important biological responses.
The consequences of ligand-specific ER conformations are becoming evident but may be complex (McKenna et al., 1999) . The coactivator SRC-1 produces a ligand-independent activation of ER while enhancing the agonist activity of the potent TAM metabolite 4-hydroxytamoxifen (Smith et al., 1997) . SRC-1 also interacts synergistically with CRE binding proteins in regulating ER-mediated transcription (Smith et al., 1996) . SMRT (corepressor) binds ER and blocks the agonist activity of 4-hydroxytamoxifen induced by SRC-1 (Smith et al., 1997) . N-CoR is a corepressor that binds TAM-occupied but not ICI 182,780-occupied ER (Jackson et al., 1997) . The functional relevance of this latter observation is consistent with the lack of full crossresistance between these two drugs in cell cultures models (Bru¨nner et al., 1993b) and in breast cancer patients (Howell et al., 1995; Robertson, 2001 ). However, a recent study found no association between N-CoR expression and outcome in TAM-treated patients (Osborne et al., 2002) .
It might be expected that increased expression or function of a protein that allows an antiestrogen to act as an agonist, or decreased expression of a coregulator that suppresses ER activity when the receptor is occupied by an antiestrogen, could confer a degree of antiestrogen resistance (Clarke and Bru¨nner, 1996; Clarke et al., 2001b) . Evidence for this in human cancers and experimental models remains somewhat limited. Expression of the corepressor N-CoR is lower in TAM-stimulated MCF-7 xenografts than in wildtype xenografts (Lavinsky et al., 1998) , but the functional relevance of the observation in human cancers is unclear. Chan et al. (1999) studied a small cohort of TAM-resistant human breast tumors (n ¼ 19) but found no difference in the expression of TIF-1, RIP140, or the corepressor SMRT. Lower levels of the coactivator SUG-1 were detected in some TAM-resistant tumors, but the consequences for antiestrogen responsiveness of reduced SUG-1 expression require further study.
Extrapolating many of these observations to specific biological functions in breast tumors is not always a simple matter. For example, most data have been obtained, of necessity, from the use of somewhat artificial experimental models with simple promoter conformations. ERE structure is variable across known estrogen-regulated genes, and a promoter's ability to bind ERs and coregulators can be affected by its local structure (Truss and Beato, 1993; Nardulli et al., 1995; Lee and Lee, 2001 ). Different ER-antiestrogen complexes also may recognize different promoter elements (Yang et al., 1996) . Thus, promoter context is likely to be important (Clarke and Bru¨nner, 1996) . Given the evidence of considerable coregulator redundancy and ubiquitous expression (McKenna et al., 1999; PlanasSilva et al., 2001; McKenna and O'Malley, 2002) , it is unclear whether measuring or affecting changes in the expression/function of any single coregulator will prove clinically useful. Attempting to affect resistance by modifying the expression of any single coregulator could be confounded by compensatory responses in other coregulators, as likely happens for mammary gland development in SRC-1 (Xu et al., 1998) and E6-AP null mice (Smith et al., 2002) . A greater degree of specificity will likely be obtained by targeting specific genes within a functionally relevant gene network (Clarke and Bru¨nner, 1996) , which would be downstream of any coregulator activities. The overall balance in the patterns and levels of expression of coactivators and coregulators also likely contributes to ER signaling and endocrine responsiveness. Clearly, cellular context is critical in assessing the role of specific coregulators in affecting a given phenotype (Clarke and Bru¨nner, 1996; Clarke et al., 2001b) .
In summary, with such redundancy and apparent lack of cell/tissue specificity, measuring the expression of specific coregulators to predict an antiestrogen-resistant phenotype may be uninformative, and affecting changes in the expression/function of any single coregulator to alter phenotype may prove difficult. We still do not know with any certainty which estrogen-regulated genes are responsible for affecting cell proliferation, cell survival, or apoptosis in breast cancer. Hence, we do not know the structure of their promoters, the coregulators their occupied receptors can recruit into functional or inactive transcription complexes, or the cellular context in which they exist in responsive and resistant cells.
Estogen receptor-independent cell signaling in antiestrogen resistance
Only a small proportion of ERÀ/PRÀ tumors respond to antiestrogens, consistent with their primary actions being mediated by ER. Nonetheless, many investigators have explored ER-independent signaling as mechanisms of antiestrogen resistance. The primary role of these effects is unclear and some occur at concentrations that are not pharmacologically relevant. Nonetheless, such activities can alter ER function or may interact with signaling downstream of ER (Figure 2 ). Since these mechanisms have been reviewed in detail (Clarke et al., 2001b) , we now only briefly discuss some of the more relevant.
Antiestrogen-induced induction of oxidative stress responses is perhaps the most widely studied ERindependent mechanism. The redox metabolism of several TAM metabolites can give rise to reactive species that can induce oxidative stress (Ye and Bodell, 1996) , and both TAM and 4-hydroxytamoxifen produce 8-hydroxy-2 0 deoxyguanosine (Okubo et al., 1998 ). TAM's ability to induce quinone reductase (Montano and Katzenellenbogen, 1997) , protein kinase C redistribution (Gundimeda et al., 1996) , and lipid peroxidation (Schiff et al., 2000) , and our observations that antiestrogen-resistant cells upregulate cytochrome c oxidases (Gu et al., 1997) and NFkB (Gu et al., 2002) also are consistent with antiestrogen effects on oxidative stress responses (reviewed by Clarke et al., 2001b) .
Other ER-independent effects include perturbations in membrane structure (Clarke et al., 1990b) , changes in protein kinase C activation and subcellular localization (O'Brian et al., 1986; Gundimeda et al., 1996) , and inhibition of the intracellular Ca þ þ binding protein calmodulin (Rowlands et al., 1995) . Some of these effects may be inter-related, since inhibition of protein kinase C also blocks calmodulin-dependent EGFR transactivation (Tebar et al., 2002) . These latter mechanisms may arise independent of ER, but would affect ER-mediated signaling. Calmodulin has been implicated as a coregulator of ER action (Biswas et al., 1998) , and EGFR-mediated signaling through MAPK may affect ER activation (see for recent reviews Clarke et al., 2001b; Santen et al., 2002) .
The extent to which these mechanisms are truly ERindependent, in that they do not affect any aspect of ER-mediated signaling, requires further study. As with TAM's effects on calmodulin, ER-independent interactions may have significant effects on ER activation and function. For example, several growth factors appear to be able to activate ER through the induction of MAPK activities capable of changing ER's phosphorylation status (Clarke et al., 2001b; Santen et al., 2002) . Other ER-independent events may interact with ER-mediated signaling downstream of ER activation. Despite these many activities, ER expression is required for most cells to respond to antiestrogens. While the importance of ER-independent signaling is unclear, many such signals may be necessary but not sufficient for affecting antiestrogen responsiveness (Clarke et al., 2001b) .
Antiestrogens, apoptosis, and cell death
Antiestrogenic exposures produce a G 0 /G 1 cell cycle arrest (Taylor et al., 1983) , whereas estrogenic exposures are primarily mitogenic and increase the proportion of cells in S and G 2 /M while reducing the proportion in G 0 /G 1 . Such effects are generally consistent with a cytostatic rather than cytotoxic effect. However, in our experience, long-term selection against antiestrogens in vitro or prolonged estrogen withdrawal from estrogendependent cells also induces cell death. Similar effects are seen in animal models. These observations are consistent with the ability of antiestrogens to reduce the incidence of ER þ breast cancers in high-risk women (chemoprevention) and produce an overall survival benefit in breast cancer patients (treatment). Initially, antiestrogens may produce a cytostatic effect that, in the longer term, results in cell death.
The precise mechanisms signaling to and responsible for antiestrogen-induced cell death are not fully understood. Most studies are consistent with an induction of an apoptotic or programmed cell death (Kyprianou et al., 1991; Huovinen et al., 1993; Zhang et al., 1999) . However, many breast cancers that acquire antiestrogen resistance still respond well to cytotoxic drugs, many of which also signal to apoptosis (Wang et al., 1996a) . Such effects could not occur if the machinery for inducing apoptosis was no longer intact or functional. Thus, the effects of antiestrogens must be upstream of effector mechanisms and reflect subtle changes in how ERs affect signaling to apoptosis. Other signaling pathways also may be important. Data from a recent study suggest Resistance to this effect in some breast cancer cells was restored by inhibition of NFkB and PI3 kinase (Toillon et al., 2002) .
Tamoxifen-stimulated phenotype in antiestrogen resistance
While antiestrogens can induce growth arrest and apoptosis, in some patients, initiation of TAM therapy is associated with rapid progression of their disease, although continuation of TAM generally produces a beneficial response (Plotkin et al., 1978; Clarysse, 1985) . This response is called 'tumor flare' and is generally attributed to the estrogenic properties often seen with low doses of TAM. TAM takes approximately 4 weeks to reach effective steady-state levels, producing a window in which patients are exposed to suboptimal and potentially estrogenic concentrations of TAM (Buckely and Goa, 1989; Etienne et al., 1989) . These tumors are clearly not resistant to TAM, in either the pharmacologic or clinical context. Tumor flare should not be confused with the clinical TAM-stimulated resistance phenotype that may occur after prolonged TAM exposure and an initial TAM response. Unlike tumor flare in previously untreated patients, evidence from MCF-7 human breast cancer xenografts suggests that some breast cancers may be initially growth inhibited by TAM, only to later become dependent on TAM for proliferation (Osborne et al., 1987; Gottardis et al., 1989; Connor et al., 2001) . These xenografts also retain the ability to be stimulated by estrogens (remain estrogen-dependent). Pharmacologically, this phenotype is not a resistance phenotype because the cells are clearly responding to the drug. However, a TAM-stimulated phenotype would represent clinical drug resistance because the nature of the response has changed in a manner that supports disease progression and would require a change in treatment. Acquired TAM dependence appears to reflect a switch in how the cells perceive TAM (as an ER agonist rather than antagonist). Several possible mechanisms may explain how this switch occurs in MCF-7 cells, including immunologic effects, ER mutations, and changes in growth factor or coregulator expression.
AIB1 and tamoxifen-stimulated growth as an antiestrogen resistance mechanism AIB-1 (amplified in breast cancer-1; also known as SRC-3, RAC3, TRAM-1, pCIP, ACTR) is a steroid hormone receptor coactivator located on chromosome 20q12 (Anzick et al., 1997) that has recently received attention as a possible contributor to antiestrogen responsiveness. AIB1 binds ER (Azorsa et al., 2001) , enhances the expression of cyclin D1 (Planas-Silva et al., 2001) , and exhibits somatic instability in some breast cancers (Dai et al., 2002) . AIB1's function as an ER coactivator produces increased transcriptional activation of ER (Anzick et al., 1997) . A novel AIB1 isoform (AIB-D3) has been recently reported that increases hormone and growth factor sensitivity and increases the estrogenicity of 4-hydroxytamoxifen to a greater degree than wild-type AIB1 (Dr Anna Riegel, Georgetown University Medical School, personal communication). The mRNA for AIB-D3 was detected at levels higher than normal cells in 7/8 breast cancers .
The data in Table 4 show some of the characteristics of AIB1 amplification and expression in breast cancers. Most studies have explored either gene amplification (found in o10%) or mRNA expression (reported in 10-64% of breast tumors). One study reported AIB1 protein expression as being above that seen in normal breast cells in approximately 10% of breast cancers by immunohistochemistry. Protein expression was detected at levels similar to or greater than those seen in normal breast cells in about 60% of ER þ tumors.
The association of AIB1 with ER status is difficult to determine from the small number of studies available. While AIB1 amplification has been associated with ERpositivity (Anzick et al., 1997) , increased AIB1 mRNA expression has been associated with ER-negativity (Bouras et al., 2001) . Similar proportions of detectable and undetectable AIB1 protein levels (B65%) were found in ER þ tumors (12/21 had undetectable expression; 11/16 had detectable expression); no significant correlation between AIB1 and either ER or PR was found (List et al., 2001) .
Approximately 10% of all ER þ breast tumors may overexpress wild-type AIB1 protein (List et al., 2001) . It remains to be seen if this 10% is primarily comprised of TAM-stimulated tumors, and/or those tumors that exhibit AIB1 gene amplification. One recent study compared AIB1 (western) and erbB2 expression. The 5-year disease-free survival was lower in those tumors expressing high levels of both AIB1 and erbB2 when compared with those expressing high levels of AIB1 and low levels of erbB2. AIB1 and number of positive lymph nodes were also correlated with shorter disease-free survival in TAM-treated compared with untreated patients (Osborne et al., 2003) .
Overexpression of AIB1 and AIB1-D3 can confer a TAM-stimulated phenotype that should also be estrogen responsive (Dr Anna Riegel, Georgetown University Medical School, personal communication). The proportion of AIB1-overexpressing cells that are dependent upon this activity for survival/proliferation is unknown. The proportion of breast biopsies that respond mitogenically to both TAM and estradiol in short-term culture (4%; see below) suggests that up to one-half of AIB1-overexpressing tumors might be TAM-stimulated. Since these tumors are predicted to retain estrogen responsiveness, and may still synthesize estrogens, many likely retain responsiveness to aromatase inhibitors.
The AIB1-overexpressing phenotype is broadly similar to some MCF-7 TAM-stimulated xenograft models. Since wild-type MCF-7 cells already overexpress AIB1 (Azorsa et al., 2001 ) and the AIB1-D3 , it is not surprising that selection against TAM might produce a TAM-stimulated phenotype. Indeed, this phenotype is already present in some MCF-7 cells without TAM selection (Dumont et al., 1996) . It remains to be seen whether this model is primarily driven by an overexpression of wild-type AIB1. Since the AIB1-D3 was identified in MCF-7 cells and is more potent, this isoform may also contribute to the phenotype of these xenografts and some human breast cancers. Indeed, this variant may prove to be more relevant in a broader context because of its ability to also affect growth factor signaling, an effect that could be important in both ER þ and ERÀ cells .
Clinical relevance of the tamoxifen-stimulated phenotype as an antiestrogen resistance mechanism Direct evidence of a TAM-stimulated resistance phenotype in breast cancer patients is difficult to find. Indirect evidence may be found from studies that assessed the frequency of a TAM withdrawal response. These responses are evident when a tumor progressing on TAM regresses upon cessation of the TAM therapy. Recently, we completed an extensive review of the literature and found 241 cases in five studies where the authors looked specifically for evidence of TAM withdrawal responses (Clarke et al., 2001b) . Responses were assessed by relatively similar criteria and could be combined into three groups: complete response, partial response, and worse than partial response. Evidence was found for only 3/241 complete responses (1.2%) and 13/ 241 partial responses (5.4%). Over 90% of cases (225/ 241) experienced a worse than partial response to TAM withdrawal (225/241; 93.4%).
Since breast tumors are highly heterogeneous, the TAM-stimulated population may not be the dominant cell population in most tumors. Thus, elimination of the TAM-dependent/stimulated population may not be sufficient to induce a complete or partial clinical response because the bulk of the tumor is independent of any TAM-induced proliferation. In our evaluation of the literature, disease stabilization was the most common beneficial response to TAM withdrawal. Disease stabilization might indicate tumors that contain populations that are no longer growth-stimulated by TAM and/or a shift in the balance between cell loss/ death and proliferation. Whatever the mechanisms, cells in these tumors are clearly not primarily dependent upon TAM for survival, since the great majority of patients (194/241; 80%) experienced disease progression upon TAM withdrawal even when disease stabilization is included as a beneficial response (Clarke et al., 2001b) .
These data imply that the majority of tumors in patients that progress on TAM treatment are not progressing because they have acquired a TAMstimulated phenotype. Indeed, the responses reported for TAM withdrawal may be a mix of several possible mechanisms, including immunologic effects or other mechanisms not directly mediated through ER. Such indirect mechanisms can be largely eliminated in in vitro models. A study of 224 human breast cancer biopsies (153 ER þ and 71 ERÀ) used an in vitro approach to measure more directly the frequency of an ER-mediated, TAM-and/or estradiol-stimulated phenotype (Nomura et al., 1990) . Primary cultures of breast cancer biopsies were studied for the ability of TAM and estradiol to induce a mitogenic response in vitro. Only 11/153 (7%) of ER þ cultures exhibited a mitogenic response to TAM, a proportion surprisingly similar to the proportion (16/241; 6.6.%) of patients estimated to experience either a complete or partial response to TAM withdrawal (Clarke et al., 2001b) .
Of interest is the observation that only 6/11 of the TAM-stimulated tumors were also stimulated by estrogen (Nomura et al., 1990) . Thus, the TAM-and estradiol-stimulated phenotype, as expressed by some MCF-7 human breast cancer xenografts, reflected only 4% (6/153) of the phenotypes of the ER þ patient biopsies and only 50% of the TAM-stimulated phenotypes.
Together, these data imply that the TAM-stimulated phenotype is only one of several that produce clinical resistance. If up to 20% of initially hormone responsive cases become TAM-stimulated to some degree (estimate includes disease stabilization responses)-by whatever combination of cellular, molecular, and/or immunologic mechanisms this stimulation is conferred-a significant number of women could be affected. Unfortunately, that still leaves the remaining 80% at risk of acquiring resistance through other mechanisms. From existing evidence, the TAM-and estradiol-stimulated phenotype exhibited by some MCF-7 xenografts may be a minor component of all TAM resistance phenotypes. Clearly, other antiestrogen resistance mechanisms exist, including antiestrogen unresponsiveness, and these remain to be identified and characterized.
Gene networks in estrogen receptor-mediated cell signaling in antiestrogen resistance
ERa expression is both necessary and sufficient to predict responsiveness to antiestrogens in a high proportion of breast tumors. Thus, antiestrogen-induced effects on ERa-mediated signaling are almost certainly of critical importance in effecting clinical responses in many tumors. Nonetheless, we still do not know the genes responsible for signaling to these effects, or whether the effects are primarily to induce cell death, repress cell survival, or a combination of both. As noted above, ER-independent events may also interact with ER-mediated signaling and this may be important in the broader context of a gene network that regulates antiestrogen responsiveness. Thus, estrogens and antiestrogens may differentially affect a gene network that contains some ER-regulated genes (Clarke and Bru¨nner, 1995, 1996) . More recently, this concept has been extended to incorporate the likely ability of integrated signals to induce apoptosis while concurrently blocking differentiation and proliferation (Clarke et al., 2001c) . It is predicted that such a network would be affected by TAM in TAM-stimulated models by signaling through patterns similar to estradiol. In antiestrogen unresponsive cells, signaling through this network may use different signaling patterns and/or exhibit differential regulation/expression of some of the same genes affected by estradiol.
The concept of a network differs from that of a signal transduction pathway in that it requires the integration of several pathways, de-emphasizes the role of wellestablished single signal transduction pathways, and acknowledges the likelihood that few complex phenotypes are likely to be driven by a single gene/pathway (Clarke et al., 2001c) . Owing to the plasticity of breast cancer phenotypes, as illustrated by the diversity of endocrine resistance phenotypes (Clarke and Bru¨nner, 1995) , the gene network concept seems reasonable. Considering signaling within the constraints of a single, linear pathway may be inappropriate. At best, such an approach is likely to produce an incomplete solution; at worst, it may be misleading.
Delineating the components of a signaling network for estrogens/antiestrogens may not be simple (Clarke and Bru¨nner, 1996) . ERs regulate gene expression through direct binding to EREs and direct interactions with other transcription factors including AP-1 and SP-1. The nature of ER activation is affected by ligand structure, and different ligands likely differentially affect the expression and function of the same members of any gene network. For example, raloxifene may regulate gene expression through novel pathways not affected by TAM or ICI 182,780 (Yang et al., 1996) , and as noted above, antiestrogens differentially affect transcription when bound to ERa compared with ERb. Regulation of the entire network or key components of the network may also be affected by ER-independent signaling, for example, as intracellular signals are perturbed by tumor-stromal cell interactions. Temporal and spatial organization of signaling components in a network is also critical. The likely complexity of network regulation has been described elsewhere (Clarke et al., 2001c) .
Accepting the principle of a network is technically demanding because it requires experimental methods to evaluate concurrently the expression of multiple genes and informatic methods capable of integrating expression pattern analyses with functional information.
Methods to obtain such high-dimensional data are well established and can be used to explore both the transcriptome and proteome of cells and tumors. However, data analysis methods for exploring gene expression microarray or two-dimensional gel electrophoresis data remain in their infancy and it may be several years before adequate methods become available and widely accepted.
A novel gene expression network in antiestrogen resistance (unresponsiveness)
We have begun to apply both proteome and transcriptome analyses (Ellis et al., 2002; Gu et al., 2002) to breast cancer cell lines, xenografts, and tumors to identify potentially important components of a large signaling network that may contribute to both estrogen independence and acquired antiestrogen resistance. Current informatic methods do not provide an easy way to uncover rapidly and correctly an entire signaling network. However, it should be possible to discover integral components of an overall network and eventually piece together these components to reveal the entire network's structure.
We first identified appropriate cellular models, derived adequate algorithms for data analysis, and began to explore the proteomes by two-dimensional gel electrophoresis and the transcriptomes by serial analysis of gene expression and gene expression microarrays. Remarkably few antiestrogen resistance models are available for study, and almost all are based on the MCF-7 human breast cancer cell line (reviewed in Clarke et al., 2001b) . MCF-7 xenografts selected against TAM almost exclusively produce a TAM-stimulated phenotype, which may not be representative of the majority of human breast cancers (see below). Thus, we established several E2-independent but responsive breast cancer cell variants with differing antiestrogen response profiles.
MCF-7 cells were first selected for an ability to grow in vivo in ovariectomized athymic nude mice. The resulting variant (MCF7/MIII) is estrogen-independent for growth both in cell culture and as xenografts (Clarke et al., 1989a) , but retains responsiveness to antiestrogens; that is, it is estrogen-independent but has an antiestrogen responsive phenotype (Clarke et al., 1989a, b) . We further selected these cells in vivo and found that repeated in vivo estrogen withdrawal, which generated the MCF7/LCC1 variant, did not substantially change the antiestrogen responsiveness of the cells (Bru¨nner et al., 1993a) . MCF7/LCC1 cells were then selected in vitro for resistance to 4-hydroxytamoxifen. The resulting MCF7/LCC2 cells are TAM-resistant but ICI 182,780 responsive (Bru¨nner et al., 1993b) . This phenotype predicted for the subsequent observation that patients responding to TAM, and then acquiring a TAM-resistant phenotype, have a high probability of retaining sensitivity to ICI 182,780 (Howell et al., 1995) . In marked contrast, MCF7/LCC1 cells selected for resistance to ICI 182,780 (MCF7/LCC9 variant) acquire resistance to ICI 182,780 and crossresistance to TAM (Bru¨nner et al., 1997) . These models represent pharmacologic models of antiestrogen resistance in the context that they no longer respond to the growth inhibitory effects of antiestrogens. Models that reflect a switch to an antiestrogen-stimulated phenotype are described above.
By comparing the proteomes and transcriptomes of several of these MCF7/LCC variants, we have begun to identify what we believe is one component of a larger gene network that may regulate antiestrogen responsiveness. The relevance of this gene subset is already under intensive investigation in functional studies in vitro and in vivo and for its ability to improve prediction of antiestrogen responsiveness in breast cancer patients.
Candidate genes
The first goal in these studies was to identify differentially expressed genes and proteins that might contribute to acquired estrogen-independent and/or antiestrogen resistance. The data in Table 5 are adapted from our most recent study (Gu et al., 2002) and show the differential regulation of genes we use below to construct one component of a putative antiestrogen responsiveness signaling network. Functional studies of the interactions described in this network are currently in progress.
Comparing the MCF7/LCC1 and MCF-7 proteomes identified nucleophosmin (NPM) as being associated with estrogen independence . NPM is a nucleolar, DNA/RNA-binding phosphoprotein (Wang et al., 1994; Herrera et al., 1995) that, when overexpressed in NIH 3T3 cells, produces a fully transformed phenotype (Kondo et al., 1997) . Downregulating NPM delays entry into mitosis (Jiang and Yung, 1999) , perhaps reflecting its differential phosphorylation by key kinases: p34 cdc2 kinase (Peter et al., 1990) , CDK2/cyclin E (Tokuyama et al., 2001) , and protein kinase C (Beckmann et al., 1992) . NPM binds the retinoblastoma protein to induce DNA polymerase a (Tchoudakova et al., 1999) and decreases susceptibility to butyrate-induced apoptosis through inducing telomerase activity (Liu et al., 1999) . Overexpression of NPM is seen in colorectal and prostate cancers (Bocker et al., 1995) . NPM is E2-regulated in breast cancer cells (Brankin et al., 1998) and anti-NPM autoantibodies are readily detected in the sera of breast cancer patients (Brankin et al., 1998) . NPM blocks the transcriptional activator functions of both YY1 (Inouye and Seto, 1994) , which regulates b-casein production in the mammary gland (Raught et al., 1994) , and the putative tumor suppressor gene interferon regulatory factor-1 (IRF-1). NPM regulates the stability and activation of p53 (Colombo et al., 2002) , implicating its activities in p53-medated effects on apoptosis, and p53 is sequested in the cytosol of TAM-resistant MCF7/LCC2 cells (Lilling et al., 2002) .
Exploring the MCF7/LCC1 and MCF7/LCC9 transcriptomes by SAGE identified several differentially expressed genes (Gu et al., 2002) . We discuss here only the human X-box binding protein-1 (XBP-1) and the nras-related gene. XBP-1 is a member of the ATF/CREB transcription factor family that activates promoters containing CREs (Clauss et al., 1996) . During liver regeneration, XBP-1 is associated with increased proliferation and reduced apoptosis (Reimold et al., 2000) , implying a survival function that may explain the role of its overexpression in hepatocellular carcinomas (Kishimoto et al., 1998) . Expressed within a cluster of genes associated with some ER þ breast tumors (Perou et al., 2000) , we have recently begun to explore XBP-1's role in normal and neoplastic breast cells.
The role of the n-ras-related gene is unclear. Ras expression is upregulated in many breast cancers (Clark and Der, 1995) and activates signaling through MAPKs that are also regulated by growth factors implicated in estrogen/antiestrogen responsiveness and mitogenesis (Dickson and Lippman, 1995; Clarke et al., 2001b; Santen et al., 2002) . These MAPKs have been implicated in phosphorylating and activating ERs, an effect that could influence antiestrogen responsiveness (Clarke et al., 2001b; Santen et al., 2002) . However, some recent studies suggest that MAPK's effects on ER do not Since the fold differences are relative to MCF7/LCC1 levels, genes upregulated in MCF7/LCC9 cells are expressed as a fraction Antiestrogen resistance R Clarke et al influence antiestrogen responsiveness (Atanaskova et al., 2002) . Exploring the MCF7/LCC1 and MCF7/LCC9 transcriptomes by gene expression microarrays implicated several genes including IRF-1, nuclear factor-kB (NFkB), early growth response gene-1 (EGR-1), epidermal growth factor receptor (EGFR), and both tumor necrosis factor-alpha (TNFa) and its receptor TNF-R1 (Gu et al., 2002) . While initially identified as an interferon-induced gene, IRF-1 has now been implicated in regulating several critical cellular functions and is a putative tumor suppressor in some cancers (Tanaka et al., 1994a, b; Yim et al., 1997) . IRF-1's tumor suppressor activities may be related to its ability to signal to apoptosis (Tanaka et al., 1994a) , which can occur in a p53-dependent or -independent manner (Tamura et al., 1995; Tanaka et al., 1996) , with or without induction of p21 waf1/cip1 (Tanaka et al., 1996) or p27 kip1 (Moro et al., 2000) , and through caspase-1 (Tamura et al., 1995 ), -7 (Sanceau et al., 2000 -8, (Suk et al., 2001) , and/or Fas-ligand (Chow et al., 2000) . Potentially related to these activities is the ability of SAPK p38, which is involved in signaling to apoptosis in response to stress, to activate IRF-1/interferon-stimulated reponse element binding (Varley and Dickson, 1999) . Consistent with putative tumor suppressor activities, one small immunohistochemical study reports reduced IRF-1 expression in neoplastic vs normal human breast tissues (Doherty et al., 2001) .
The consequence of NFkB activation is cell context specific (Voegel et al., 1996) , but it is generally considered antiapoptotic in most cancer cells. Several aspects of normal mammary gland development appear dependent upon NFkB activity (Clarkson and Watson, 1999) , likely reflecting its regulation by both estrogens and growth factors (Nakshatri et al., 1997; Biswas et al., 2000) . Elevated NFkB activity arises early during neoplastic transformation in the rat mammary gland (Kim et al., 2000) . Widely expressed in human and rat mammary tumors (Sovak et al., 1997; Cogswell et al., 2000) , upregulation of NFkB is associated with estrogen independence (Nakshatri et al., 1997; Clarkson and Watson, 1999) . NFkB is the only protein known to induce BRCA2 expression (Welcsh and King, 2001 ). Several excellent reviews on NFkB signaling are available (Bours et al., 2000; Baldwin, 2001; Karin et al., 2002) .
EGR-1 is a transcription factor with proapoptotic activity (Das et al., 2000) and is downregulated in DMBA-induced mammary adenocarcinomas in rats and mouse and human breast cancer cells (Huang et al., 1997) . c-myc is a major regulator of breast cancer proliferation and survival (Liao and Dickson, 2000) and is among the genes downregulated by EGR-1 (Hoffman et al., 2002) . EGR-1 also blocks NFkB function (Chapman and Perkins, 2000) and can stimulate apoptosis through cooperation with p21 waf1/cip1 and transactivation of p53 (Liu et al., 1998) . Superoxide dismutase (SOD) expression is increased in MCF7/ LCC9 cells (Gu et al., 2002) and in TAM-stimulated MCF-7 xenografts (Schiff et al., 2000) ; SOD overexpression was previously implicated in resistance to TNFa (Zyad et al., 1994) . A TNFa-mediated pathway for signaling to apoptosis occurs in MCF-7 cells (Burow et al., 1998; Egeblad and Jaattela, 2000) , and measuring serum TNF concentrations may be a useful prognostic marker in breast cancer patients (Sheen-Chen et al., 1997) . Furthermore, IRF-1 expression is induced by TNFa in some cells (Mori et al., 1999) .
One component of a gene network
Using the data from our proteome and transcriptome studies and from other published studies, we have begun to construct a gene expression network for signaling in antiestrogen responsiveness (Figure 3) . Studying a variant that is crossresistant to triphenylethylenes and steroidal antiestrogens (MCF7/LCC9) provided the opportunity to identify more broadly based resistance signaling than might be obtained from a study of TAMonly resistance (e.g., MCF7/LCC2 phenotype). The apparent consistency of the interactions among the
Signaling to Apoptosis/Cell Cycle Arrest For example, the low levels of IRF-1 in MCF7/LCC9 cells are unable to induce EGFR, which remains low in these cells. Redundancy is evident; for example, the upregulation of NFkB and ras may compensate for low EGFR expression because they signal downstream of the EGFR's kinase activity. Signaling through this network component is expected to be different between sensitive and resistant cells and likely also different among some populations with the same phenotype. For example, not all resistant cells need to modify gene expression in the same pattern as apparently adopted by MCF7/LCC9 cells. Since ER-mediated effects are critical in antiestrogen-induced signals in sensitive cells, these cells may signal through the network component primarily comprising ER-regulated genes. While the interactions in this figure are consistent with published data, the network as represented is not intended to be complete and the regulation of some genes may be more complex than alluded to here. As we further evaluate signaling in these cells, we may identify additional components of this network. {} ¼ receptor-ligand complex; m ¼ expression is increased; k ¼ expression is reduced; other arrows show direction of signal transduction; > ¼ inhibition of indicated gene/function; ¼ inability to induce substantially next signal or influence next event due to low/reduced expression/activity relatively few genes incorporated into our network component is surprising. EGF-R induces expression of EGR-1 (Tsai et al., 2000) , and expression of both genes is lower in MCF7/LCC9 cells (Gu et al., 2002) . Since EGR-1 inhibits NFkB function (Chapman and Perkins, 2000) , its low expression may contribute to the increased NFkB activity in these cells (Gu et al., 2002) . IRF-1 induces EGF-R mRNA (Rubinstein et al., 1998) , and IRF-1 levels are lower in MCF7/LCC9 cells (Gu et al., 2002) . IRF-1 is induced by TNFa/TNF-R1 (Mori et al., 1999) , both of which are also concurrently downregulated in MCF7/ LCC9 cells, perhaps explaining their lower IRF-1 levels. IRF-1 can act as a tumor suppressor and signal to apoptosis through both p53-dependent and -independent pathways (Taniguchi, 1997) . These observations may reflect IRF-1's ability to affect caspase activity, since caspase activation and induction of apoptosis are implicated in affecting antiestrogen responsiveness (Mandlekar et al., 2000a, b) . Overexpression of caspase-1, which regulates apoptosis in normal mammary epithelial cells (Boudreau et al., 1995) , is known to be lethal in MCF-7 cells (Keane et al., 1996) . In these models, signaling through caspase-3 is unlikely because the gene is truncated in MCF-7 cells (Friedrich et al., 2001) ; signaling through caspase-7 may dominate.
Interferons (IFNs) and TNF act synergistically to induce gene expression, an effect that appears driven by protein-protein interactions between IRF-1 and NFkB (Drew et al., 1995; Neish et al., 1995) . IRF-1 can induce degradation of IkBa in some cells (Kirchoff et al., 1999) . IRF-1 : NFkB heterodimers affect expression of the ATF-2/jun (Escalante et al., 1998) , RANTES (Lee et al., 2000) , VCAM-1 (Neish et al., 1995) , IL-6 (Sanceau et al., 1995) , and MHC class 1 genes (Drew et al., 1995) . Altered AP-1 expression (includes jun) is implicated in the TAM-stimulated antiestrogen resistance phenotype (Schiff et al., 2000) , RANTES expression correlates with a poor prognosis (Luboshits et al., 1999) , VCAM-1 is involved in angiogenesis and metastasis in breast tumors , and autocrine production of IL-6 is associated with drug resistance in breast cancer cells (Conze et al., 2001) .
Unlike IRF-1, NPM expression is increased in MCF7/LCC9 cells compared with MCF7/LCC1 cells. NPM can function as an oncogene, its overexpression fully transforming NIH 3T3 cells in an assay for oncogenic potential (Kondo et al., 1997) . Levels of autoantibodies to NPM increase in patients 6 months prior to recurrence. Consistent with an antiestrogenic regulation of NPM, the levels of NPM autoantibodies are lower in breast cancer patients who received TAM (Brankin et al., 1998) . Concurrent upregulation of NPM and downregulation of IRF-1 suggest a novel signaling pathway in antiestrogen resistance. Both are estrogenregulated genes in MCF-7 cells, IRF-1 expression being suppressed and that of NPM being induced (Skaar et al., , 2000 . Through its direct binding to IRF-1, NPM inhibits the transcription regulatory activities of IRF-1 (Kondo et al., 1997) . Overexpression of NPM may eliminate the remaining IRF-1 activity, blocking its ability to initiate an apoptotic caspase cascade, and/or induce p21 waf/1cip1 (Coccia et al., 2000) and cooperate with p53 in signaling to growth arrest and apoptosis (Tanaka et al., 1994a (Tanaka et al., , 1996 . XBP-1 acts through its ability to regulate genes containing CRE in their promoters (Clauss et al., 1996) . A cAMP-dependent pathway that inhibits IRF-1 transactivation has been described (Delgado et al., 1999) ; XBP-1 activation of this pathway could suppress further the already low IRF-1 activity in some antiestrogen-resistant cells.
N-ras-induced signaling may also be important and implies an upregulation of ras-induced signaling in resistant cells. Such increased signaling may partly abrogate the need for growth factor-induced signaling through autocrine, paracrine, or intracrine stimulation (Clarke et al., 2001b) because increased ras activation is downstream of several growth factor receptors implicated in breast cancer (Santen et al., 2002) . For example, cells may be capable of surviving when EGFR levels are reduced (Table 5 ) because loss of EGFR signaling is compensated by a downstream upregulation of ras-mediated signaling. Low IRF-1 expression may also contribute to the effects of ras signaling because IRF-1 induces lysyl oxidase (Sers et al., 2002) , which is implicated in reversing ras-induced malignant transformation (Contente et al., 1999; Nozawa et al., 1999) .
Some of the genes we found have been implicated in antiestrogen resistance in other studies, most notable being EGF-R and its family member c-erbB2 (Kurokawa et al., 2000; Welch and Clarke, 2002; Konecny et al., 2003) . AKT (PerezTenorio and Stal, 2002) , c-myc (Carroll et al., 2002) , cyclin D1 (Varma and Conrad, 2002) , p53, p21 waf1/cip1 (Fattman et al., 1998) , and AP-1 (Schiff et al., 2000) may also contribute to antiestrogen responsiveness. We have incorporated some of this knowledge into the network in Figure 3 , particularly where these genes may interact with those identified in our models. Several genes are thought to be downstream of signaling from growth factor receptors implicated in either phosphorylating/ activating ER and/or inducing mitogenesis and affecting antiestrogen responsiveness (Chan et al., 2001; Varma and Conrad, 2002) . For example, the type I insulin-like growth factor receptor and c-erbB2 can activate AKT, which is often upstream of NFkB (Martin et al., 2000) . Several growth factors activate MAPK signaling to mitogenesis and signal through activation of ER. For simplicity, we have not shown all of these possible interactions in Figure 3 .
Functional studies
We acknowledge that the gene network component in Figure 3 is somewhat speculative. Furthermore, it is unlikely to be regulated in the same way in TAMstimulated models that perceive TAM as an estrogen. For example, in TAM-stimulated models, key network components could be perturbed in the same manner as expected with estradiol treatment.
One approach to assessing the likely validity of selected genes in our network component is to explore their functional activities and abilities to affect antiestrogen responsiveness in experimental models. We have begun several studies to further assess the likely functional relevance of our observations and support the gene network component in Figure 3 . Transcriptional activation of XBP-1 and NFkB was studied using established promoter-reporter assays (CRE promoterreporter assay for XBP-1). As predicted in the transcriptome analyses, increased basal transcription of both promoters was observed. Further studies showed that the ability of ICI 182,780 to inhibit NFkB activation is lost in the resistant cells. Preliminary data from our laboratory imply that the ability of antiestrogens to induce IRF-1 is also lost in resistant cells . Consistent with our earlier hypotheses (Clarke and Lippman, 1992) , these data show significant changes in the endocrine regulation of some ERregulated genes. We found no evidence for endocrine regulation of CRE activation in either responsive or resistant cells. However, resistant cells exhibit a significant fourfold increase in CRE activation, reflecting the fourfold increase in its expression predicted from the SAGE study. These observations suggest at least some general resistance mechanisms: an overexpression and loss of endocrine regulation of some genes that are ERregulated in responsive cells, a downregulation and loss of endocrine regulation of some genes that are ERregulated in responsive cells, and an upregulation of some endocrine unresponsive genes.
To study functional relevance further, the sensitivity of our variants to inhibition of NFkB activation by parthenolide was explored. Parthenolide, which is currently in early clinical trials, binds NFkB in a highly stereospecific manner (Garcia-Pineres et al., 2001) and inhibits the IkB kinase repressor of NFkB (Hehner et al., 1999; Patel et al., 2000) . We would expect that, if NFkB is providing a survival function, MCF7/LCC9 cells might be more dependent upon this activity. Indeed, MCF7/LCC9 cells are significantly more sensitive to growth inhibition by parthenolide than their MCF7/ LCC1 parental cells (Gu et al., 2002) . Thus, some cells may survive antiestrogen exposure by upregulating estrogen-regulated survival factor(s) concurrent with the loss of their ER-mediated regulation. While we first need to confirm and extend these observations, parthenolide may prove useful in combination with Faslodex or other antiestrogens to either increase responsiveness and/or delay the appearance of resistant disease. Functional studies into the activities of the other genes in this network and investigations into their power to better predict antiestrogen responsiveness in patients are in progress.
Conclusions and future prospects
Acquired antiestrogen resistance likely comprises both true antiestrogen unresponsiveness (the major phenotype) and antiestrogen-stimulated growth (probably a minor phenotype). Several resistance mechanisms exist and, with the exception of loss of ER expression, these mechanisms may not be driven by a single gene or single signaling pathway. Consequently, we continue to develop the concept that an integrated gene network exists that allows cells a significant degree of plasticity in how they signal through this network (Clarke and Bru¨nner, 1995, 1996; Clarke et al., 2001c) . More recently, we have begun to identify candidate genes in one component of this network and to explore their likely functional relevance in experimental models and ability to predict patient outcome. As we and others explore the transcriptomes and proteomes of experimental models and patient samples, additional components of this network may become apparent. Ultimately, understanding how breast cancer cells coordinate a response to antiestrogens, and overcome the growth inhibitory nature of the resulting signaling, may lead to better treatments and more powerful predictors of clinical response.
Some dietary components can modify the ability of TAM to inhibit the growth of ER þ and perhaps also ERÀ breast cancer cells. These dietary components might be those that alone are believed to affect recurrence of breast cancer. However, when consumed in combination with TAM, various dietary components could either potentiate or inhibit TAM's actions. Examples of unexpected findings are the studies of Ju et al. (2002) and Depypere et al. (2000) , who showed that genistein or tangeretin prevents TAM from inhibiting growth of malignant breast cells. Currently, only a few published studies have examined the impact of nutrition on TAM's therapeutic effects, and it is likely that other dietary factors can modify TAM's ability to inhibit breast cancer growth.
The clinical use of antiestrogens, and TAM in particular, may change in the future. Data from some recent studies suggest that the current generation of aromatase inhibitors may be more effective than antiestrogens as first-line endocrine treatment for ER þ metastatic breast cancer and as adjuvant therapy for ER þ breast primaries (Buzdar and Howell, 2001; Ellis et al., 2001) . Nonetheless, the American Society of Clinical Oncology's Technology Assessment Working Group continues to recommend 5 years of adjuvant TAM as the standard therapy for women with ER þ breast cancer . In terms of chemoprevention, the recommendations include the use of TAM vs participation in a clinical trial that involves the administration of raloxifene, any aromatase inhibitor, or any retinoid only within the context of chemoprevention .
